-
公开(公告)号:AU2019359885B2
公开(公告)日:2024-01-18
申请号:AU2019359885
申请日:2019-10-17
Applicant: ARRAY BIOPHARMA INC
Inventor: BLAKE JAMES F , BOYS MARK LAURENCE , CHICARELLI MARK JOSEPH , COOK ADAM , ELSAYED MOHAMED S A , FELL JAY B , FISCHER JOHN P , HINKLIN RONALD JAY , MCNULTY OREN T , MEJIA MACEDONIO J , RODRIGUEZ MARTHA E , WONG CHRISTINA E
IPC: C07D401/04 , A61K31/498 , A61K31/4985 , A61P35/00 , C07D471/04 , C07D519/00
Abstract: Compounds of Formula la or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases in the view of their ability to inhibit SHP2. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for
-
公开(公告)号:ZA202101960B
公开(公告)日:2023-11-29
申请号:ZA202101960
申请日:2021-03-24
Applicant: ARRAY BIOPHARMA INC
Inventor: HINKLIN RONALD JAY , COOK ADAM , MCNULTY OREN T , BLAKE JAMES F , BOYS MARK LAURENCE , CHICARELLI MARK JOSEPH , ELSAYED MOHAMED S A , FELL JAY B , FISCHER JOHN P , MEJIA MACEDONIO J , RODRIGUEZ MARTHA E , WONG CHRISTINA E
Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed
-
公开(公告)号:AU2018369759B2
公开(公告)日:2022-11-24
申请号:AU2018369759
申请日:2018-11-14
Applicant: ARRAY BIOPHARMA INC , MIRATI THERAPEUTICS INC
Inventor: BLAKE JAMES F , BURGESS LAURENCE E , CHICARELLI MARK JOSEPH , CHRISTENSEN JAMES GAIL , COOK ADAM , FELL JAY BRADFORD , FISCHER JOHN P , MARX MATTHEW ARNOLD , MEJIA MACEDONIO J , SAVECHENKOV PAVEL , VIGERS GUY P A , SMITH CHRISTOPHER RONALD , RODRIGUEZ MARTHA E
IPC: C07D401/06 , C07D401/14
Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
-
公开(公告)号:CA2934709C
公开(公告)日:2022-08-30
申请号:CA2934709
申请日:2014-12-29
Applicant: ARRAY BIOPHARMA INC , GENENTECH INC
Inventor: BLAKE JAMES F , COOK ADAM , GAUDINO JOHN , GUNAWARDANA INDRANI W , HICKEN ERIK JAMES , HUNT KEVIN W , LYON MICHAEL , METCALF ANDREW T , MOHR PETER J , MORENO DAVID A , NEWHOUSE BRAD , REN LI , SCHWARZ JACOB , CHEN HUIFEN , GAZZARD LEWIS , SCHMIDT JANE , DO STEVE
IPC: C07D487/04 , A61K31/444 , A61K31/506 , A61P29/00
Abstract: Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are selective inhibitors of ERK and are useful for the treatment of diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro , in situ, and in vivo diagnosis, prevention or treatment of such diseases, or associated pathological conditions are disclosed.
-
公开(公告)号:AU2019330017B2
公开(公告)日:2022-05-26
申请号:AU2019330017
申请日:2019-08-29
Applicant: ARRAY BIOPHARMA INC
Inventor: HINKLIN RONALD JAY , ALLEN SHELLEY , BARBOUR PATRICK , COOK ADAM , DAHLKE JOSHUA , GAUDINO JOHN , LAIRD ELLEN , MCNULTY OREN T , ZHAO QIAN
IPC: C07D471/04 , A61K31/437 , A61P35/00
Abstract: Provided herein are compounds of the Formula (I): and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein R
-
公开(公告)号:CR20210364A
公开(公告)日:2021-08-18
申请号:CR20210364
申请日:2020-01-02
Applicant: ARRAY BIOPHARMA INC
Inventor: MCNULTY OREN T , COOK ADAM , HINKLIN RONALD JAY
IPC: A61K31/495 , A61P35/00 , C07D401/14
Abstract: En la presente, se proporcionan compuestos de la Fórmula I :
-
公开(公告)号:AU2020205035A1
公开(公告)日:2021-07-22
申请号:AU2020205035
申请日:2020-01-02
Applicant: ARRAY BIOPHARMA INC
Inventor: COOK ADAM , HINKLIN RONALD JAY , MCNULTY OREN T
IPC: C07D401/14 , A61K31/4709 , A61K31/495 , A61P35/00
Abstract: Provided herein are compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X
-
公开(公告)号:CO2021008535A2
公开(公告)日:2021-07-19
申请号:CO2021008535
申请日:2021-06-29
Applicant: ARRAY BIOPHARMA INC
Inventor: COOK ADAM , HINKLIN RONALD JAY , MCNULTY OREN T
IPC: C07D401/14 , A61K31/4709 , A61K31/495 , A61P35/00
Abstract: En la presente, se proporcionan compuestos de la Fórmula I: I o sales de estos aceptables desde el punto de vista farmacéutico, en donde X1, X2, X3, R1, R2, R3, R4, R5, R6 y R7 son como se definen en la presente, que son inhibidores de una o más quinasas TAM y/o quinasa c-Met, y son útiles en el tratamiento y la prevención de enfermedades que se pueden tratar con un inhibidor de quinasa TAM y/o un inhibidor de quinasa c-Met.
-
公开(公告)号:CR20210098A
公开(公告)日:2021-07-01
申请号:CR20210098
申请日:2019-08-29
Applicant: ARRAY BIOPHARMA INC
Inventor: ALLEN SHELLEY , LAIRD ELLEN , COOK ADAM , ZHAO QIAN , HINKLIN RONALD JAY , DAHLKE JOSHUA , GAUDINO JOHN , MCNULTY OREN T , BARBOUR PATRICK
IPC: A61K31/437 , A61P35/00 , C07D471/04
Abstract: La presente invención se refiere a compuestos de la Fórmula I : y estereoisómeros, tautómeros y sales de los mismos farmacéuticamente aceptables, en donde R 1 , R 2 , R 9 , X 1 y G son como se definen en la presente, los cuales son inhibidores de una o más cinasas TAM y/o cinasa c-Met, y son útiles en el tratamiento y prevención de enfermedades las cuales pueden ser tratadas con un inhibidor de cinasa TAM y/o un inhibidor de cinasa c-Met.
-
公开(公告)号:AU2017342027B2
公开(公告)日:2021-04-01
申请号:AU2017342027
申请日:2017-10-10
Applicant: ARRAY BIOPHARMA INC
Inventor: ANDREWS STEVEN W , ARONOW SEAN , BLAKE JAMES F , BRANDHUBER BARBARA J , COLLIER JAMES , COOK ADAM , HAAS JULIA , JIANG YUTONG , KOLAKOWSKI GABRIELLE R , MCFADDIN ELIZABETH A , MCKENNEY MEGAN L , MCNULTY OREN T , METCALF ANDREW T , MORENO DAVID A , RAMANN GINELLE A , TANG TONY P , REN LI , WALLS SHANE M
IPC: C07D471/04 , A61K31/437 , A61P35/00
Abstract: Provided herein are compounds of the Formula I: (I) or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X
-
-
-
-
-
-
-
-
-